Implementation of P.L. 115-123, the Bipartisan Budget Act (BBA) of 2018. H.R. 3976, "Access to Marketplace Insurance Act."
H.R. 2644, "Chronic Kidney Disease Improvement in Research and Treatment Act of 2017."
S. 1890, "Chronic Kidney Disease Improvement in Research and Treatment Act of 2017."
Guaranteeing Medigap insurance for End Stage Renal Disease (ESRD) patients.
Providing the ability of ESRD patients to enroll in Medicare Advantage (MA).
KidneyX, HHS initiative to accelerate the development of drugs, devices and digital health tools for prevention, diagnosis and treatment of Chronic Kidney Disease (CKD).
Withdrawal of interim final rule on charitable premium assistance payments. Proposed rule on CY 2019 ESRD Prospective Payment System (PPS) and Quality Improvement Program (QIP).
Payment for new drugs and expansion of Transitional Drug Add-On Payment (TDAPA)in the ESRD PPS. 
Medicare Part D coverage for outpatient drugs, including patient coinsurance and manufacturer obligations in the coverage gap. 
Medicare Secondary Payer period for dialysis patients.
BUD - Budget/Appropriations HCR - Health Issues MMM - Medicare/Medicaid
2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
AKEBIA THERAPEUTICS, INC.
245 First Street, Suite 1100, Cambridge, MA, 02142, US
SARA FROELICH SARA FROELICH SARA FROELICH